文献速递新发突发、热带与寄生虫病细菌感染、耐药与抗菌药物

全球基金区域青蒿素耐药倡议对大湄公河次区域疟疾控制与消除的影响

Impact of the Global Fund Regional Artemisinin-resistance Initiative on malaria control and elimination in the Greater Mekong subregion of southeast Asia.
PubMed 文献 · Lancet Infect Dis · 2025-02-26

为应对大湄公河次区域(GMS)恶性疟原虫对青蒿素及青蒿素联合疗法伙伴药部分耐药,区域青蒿素耐药倡议(RAI)于2014年成立。柬埔寨、老挝和越南的疟疾病例数从2010年的数十万例降至2023年的2313例,其中仅246例由恶性疟原虫引起。缅甸疟疾病例上升及跨境溢出令人担忧,需紧急行动。

要点

  • 柬埔寨、老挝和越南疟疾病例从2010年数十万例降至2023年2313例,其中恶性疟246例。
  • 关键措施包括社区和流动疟疾工作者网络、改进监测、主动病例检测、特定风险群体化学预防和靶向给药。
  • 缅甸疟疾病例上升并出现跨境溢出,需紧急行动;GMS经验可借鉴给撒哈拉以南非洲。

核心结论

  • RAI使东GMS国家接近消除最致命的恶性疟原虫,但缅甸疟疾病例上升及跨境溢出需紧急行动。

研究设计与样本

  • 本文为Lancet Infect Dis发表的区域倡议效果总结,未报告系统检索范围或样本量。

主要发现

  • 柬埔寨、老挝和越南疟疾病例数从2010年数十万例降至2023年2313例,其中仅246例由恶性疟原虫引起。
  • 成功关键包括早期诊断治疗可及性差人群、改进监测、主动病例检测、特定风险群体化学预防和靶向给药。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Responding to the emergence of Plasmodium falciparum partial resistance to artemisinins and partner drugs of artemisinin-based combination therapies in the Greater Mekong subregion (GMS) of southeast Asia, the Regional Artemisinin-resistance Initiative (RAI) was established in 2014 and has made remarkable progress in eliminating falciparum malaria. In Cambodia, Laos, and Viet Nam, the number of malaria cases has declined from hundreds of thousands in 2010 to 2313 cases in 2023, with only 246 caused by falciparum malaria. The key components of this success have been an effective package of interventions curbing malaria transmission, with an emphasis on early diagnosis and treatment in hard-to-reach populations through an extended and well organised network of community and mobile malaria workers; improved surveillance systems; and evidence-driven implementation of intensified approaches such as active case detection, chemoprevention in specific risk groups, and targeted drug administration. The RAI is funded by the Global Fund to Fight AIDS, Tuberculosis and Malaria and governed by a closely collaborating Regional Steering Committee, including technical partners, key development partners, and stakeholders from ministries of health, national malaria control programmes, civil society organisations, the private sector, academia, and regional multilateral organisations. The RAI has brought the countries of the eastern GMS close to eliminating P falciparum, the deadliest malaria-causing Plasmodium species. Nonetheless, a worrying rise in malaria cases in Myanmar with cross-border spillover requires urgent action. Lessons learned from the RAI's approach to antimalarial drug resistance in the GMS can inform countries in sub-Saharan Africa, where artemisinin partial resistance has now also emerged.

来源:Lancet Infect Dis,查看原文。版权归原作者所有。

引用

  1. Pley C, Gibbs H, Sudathip P, et al. Impact of the Global Fund Regional Artemisinin-resistance Initiative on malaria control and elimination in the Greater Mekong subregion of southeast Asia. Lancet Infect Dis. 2025. PMID: 40023184. doi:10.1016/S1473-3099(25)00013-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。